Innate Pharma S.A. (IPHA) Stock: Price, Forecast & Analyst Target
Innate Pharma S.A. (IPHA) — MoonshotScore 17/100 (Weak band), calculated Oct 5, 2026. Price $1.56 (-1.89%), as of the Oct 2, 2026 trading session; market cap $146M.
Educational signal · not a buy or sell recommendation · How to read this
Innate Pharma S.A. · IPHA · NASDAQ
Innate Pharma S.A. is a biotechnology firm specializing in therapeutic antibodies for oncology and inflammatory diseases.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Innate Pharma (IPHA)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, a fragile balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Quiet.
- quarterly revenue $4M (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 3 of 8
- Altman Z -27.22 · Piotroski F 3
Holding back: balance-sheet strain, a rich price, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak |
The score was 17 in the stored Oct 4, 2026 snapshot and remains 17 in the current publication computed Oct 5, 2026 (0). This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.56 | |
| Change on the day | -1.89% | |
| 52-week range | $1.17 – $2.71 | |
| Market capitalisation | $146M | |
| Shares traded on the day | 92.7K |
Price & events
Other perspectives
Council score for Innate Pharma (IPHA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 4, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the IPHA film — every key number, told as a short cinematic story
~2 min · open the film
What is Innate Pharma (IPHA), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Innate Pharma S.A. (IPHA) is listed on NASDAQ. It employs 163 people and is led by Jonathan E. Dickinson. In Q2 FY2026 it reported revenue of $4M and net income of -$22M. The market values it at $146M.
What do the latest results show for Innate Pharma (IPHA)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $4M. Against analyst estimates the company has EPS beat 3 of 8 reports.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $4M | -$22M | -$0.23 (diluted) |
| Q2 FY2025 | $5M | -$24M | -$0.28 (diluted) |
| Q4 FY2024 | $308,689.44 | -$28M | -$0.34 (diluted) |
What are the financial strengths and risks for Innate Pharma (IPHA)?
Short answer
What is holding it back is balance-sheet strain, a rich price, soft growth. The distress and quality screens read Altman Z -27.22 · Piotroski F 3. Trailing ratios: ROA -78.4% · current ratio 1.27 · earnings yield -34.1% · free-cash-flow yield -35.7%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -27.22 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Innate Pharma (IPHA)?
Short answer · as of
Current published price targets run low $4.00 · high $9.00 · consensus $6.67 · median $7.00 against a quoted price of $1.56 (as of Oct 2, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Innate Pharma compare with its peers?
Short answer
Innate Pharma's score ranks 5th of 5 in the bounded comparison shown, against 4 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $61.15 Oct 2, 2026 | $125B | 92 5-pillar Oct 5, 2026 | |
| $403.04 Oct 2, 2026 | $218B | 84 5-pillar Oct 5, 2026 | |
| $141.00 Oct 2, 2026 | $268B | 84 5-pillar Oct 5, 2026 | |
| $144.74 Oct 2, 2026 | $179B | 65 5-pillar Oct 5, 2026 | |
| Innate Pharma (IPHA) — this page | $1.56 | $146M | 17 |
| $52.25 Oct 2, 2026 | $333B | — Model unavailable | |
| $9.96 Date unavailable | $119M | — Model unavailable | |
| $4.49 Date unavailable | $184M | — Model unavailable | |
| $5.71 Date unavailable | $206M | — Model unavailable | |
| $2.71 Date unavailable | $218M | — Model unavailable | |
| $2.79 Date unavailable | $222M | — Model unavailable | |
| $17.08 Date unavailable | $90.6M | — Model unavailable | |
| $9.75 Date unavailable | $88.2M | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $4.00 – $9.00
- Consensus target
- $6.67
- Median target
- $7.00
Consensus record · Captured .
Measured against a quoted price of $1.56 (as of Oct 2, 2026).
What has been published about Innate Pharma (IPHA)?
Investor Questions: IPHA Stock
These answers are editorial: 1 of these 9 answers is drawn from the IPHA research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for IPHA?
IPHA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is IPHA a good stock to buy?
Stock Expert AI does not rate IPHA buy, sell or hold. Innate Pharma S.A. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the IPHA stock price today?
The last price recorded on this page for Innate Pharma S.A. (IPHA) is $1.56, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the IPHA price target?
The analyst consensus price target for Innate Pharma S.A. (IPHA) is $6.67 (range $4.00 to $9.00, median $7.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What is Innate Pharma S.A.'s drug pipeline status?
Innate Pharma S.A. has a diverse drug pipeline featuring several clinical-stage assets. Key candidates include Monalizumab, currently in Phase III trials for advanced solid tumors, and Lacutamab, which is in Phase II trials for cutaneous T-cell lymphoma.
What are the key factors to evaluate for IPHA?
Innate Pharma S.A. (IPHA) holds a MoonshotScore in the low range. Analysts target $6.67 (+328%). No dividend yield, typical for biotechnology firms focusing on reinvestment into R&D. Not financial advice.
How frequently does IPHA data refresh on this page?
IPHA's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven IPHA's recent stock price performance?
Innate Pharma S.A. (IPHA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Robust clinical pipeline with multiple assets in advanced stages of development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IPHA overvalued or undervalued right now?
Innate Pharma S.A. (IPHA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $6.67 (+328%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (20 figures)
The 20 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 12 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $1.56 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T04:14:29.088Z. | |
px.change | Change on the day | -1.89% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $146M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-05T04:14:27.968Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.03 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $4M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 92.7K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$22M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 3 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $4.00 · high $9.00 · consensus $6.67 · median $7.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $4.00 – $9.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $6.67 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $7.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-19 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -27.22 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $1.17 – $2.71 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
id.employees | Employees | 163 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
id.ceo | Chief executive | Jonathan E. Dickinson | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROA -78.4% · current ratio 1.27 · earnings yield -34.1% · free-cash-flow yield -35.7% | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 17 of 100 · Weak · pillars 37 / 8 / 15 / 10 / 49 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 17 (stored snapshot Oct 4, 2026) → 17 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.